Technology Briefing

Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine is taking a growing beating in the scientific literature, as anecdotal evidence of significant side effects is starting to trickle in. Partner Wyeth-Ayerst last week scrambled to keep up, announcing that it is working with Mayo Clinic Researchers to evaluate any links between valvular heart disease and weight loss drugs.

In July, Mayo researchers announced a possible association between rare heart valve disorders and fenfluramine-phentermine (fen-phen) obesity therapy (see BioCentury July 14).